This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Intellectual Property,
Civil Litigation

Nov. 5, 2020

Induced infringement ruling could have far-reaching effects

A recent Federal Circuit ruling has potentially far-reaching impacts in cases involving allegations of induced infringement.

Daniel Knauss

Partner
Cooley LLP

Alissa Wood

Associate
Cooley LLP

Cameron Vanderwall

Associate
Cooley LLP

Michelle Rhyu

Partner
Cooley LLP

The U.S. Court of Appeals for the Federal Circuit's recent precedential decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. has potentially far-reaching impacts in cases involving allegations of induced infringement. The court reinstated a jury's verdict that Teva infringed GSK's patented method of using its Coreg drug product, even though Teva's product was initially launched with a skinny label that carved-out the infringing...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up